Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

256 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Tumor-intrinsic oncogene pathways mediating immune avoidance.
Spranger S, Gajewski TF. Spranger S, et al. Among authors: gajewski tf. Oncoimmunology. 2015 Aug 31;5(3):e1086862. doi: 10.1080/2162402X.2015.1086862. eCollection 2016 Mar. Oncoimmunology. 2015. PMID: 27141343 Free PMC article. Review.
Rational development of tumour antigen-specific immunization in melanoma.
Gajewski TF, Fallarino F. Gajewski TF, et al. Ther Immunol. 1995 Aug;2(4):211-25. Ther Immunol. 1995. PMID: 9358613 Review.
The immune system as anti-tumor sentinel: molecular requirements for an anti-tumor immune response.
Markiewicz MA, Gajewski TF. Markiewicz MA, et al. Among authors: gajewski tf. Crit Rev Oncog. 1999;10(3):247-60. Crit Rev Oncog. 1999. PMID: 10468184 Review.
Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma.
Peterson AC, Harlin H, Gajewski TF. Peterson AC, et al. Among authors: gajewski tf. J Clin Oncol. 2003 Jun 15;21(12):2342-8. doi: 10.1200/JCO.2003.12.144. J Clin Oncol. 2003. PMID: 12805336 Clinical Trial.
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells.
Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, Gajewski TF. Blank C, et al. Among authors: gajewski tf. Cancer Res. 2004 Feb 1;64(3):1140-5. doi: 10.1158/0008-5472.can-03-3259. Cancer Res. 2004. PMID: 14871849
Overcoming immune resistance in the tumor microenvironment by blockade of indoleamine 2,3-dioxygenase and programmed death ligand 1.
Gajewski TF. Gajewski TF. Curr Opin Investig Drugs. 2004 Dec;5(12):1279-83. Curr Opin Investig Drugs. 2004. PMID: 15648949 Review.
Metabolic mechanisms of tumor resistance to T cell effector function.
Cham CM, Gajewski TF. Cham CM, et al. Among authors: gajewski tf. Immunol Res. 2005;31(2):107-18. doi: 10.1385/IR:31:2:107. Immunol Res. 2005. PMID: 15778509 Review.
Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites.
Harlin H, Kuna TV, Peterson AC, Meng Y, Gajewski TF. Harlin H, et al. Among authors: gajewski tf. Cancer Immunol Immunother. 2006 Oct;55(10):1185-97. doi: 10.1007/s00262-005-0118-2. Epub 2006 Feb 9. Cancer Immunol Immunother. 2006. PMID: 16468035
Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy.
Velicu S, Han Y, Ulasov I, Brown IE, El Andaloussi A, Gajewski TF, Lesniak MS. Velicu S, et al. Among authors: gajewski tf. J Neuroimmunol. 2006 May;174(1-2):74-81. doi: 10.1016/j.jneuroim.2006.01.016. Epub 2006 Feb 28. J Neuroimmunol. 2006. PMID: 16504307
Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment.
Gajewski TF. Gajewski TF. Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2326s-2330s. doi: 10.1158/1078-0432.CCR-05-2517. Clin Cancer Res. 2006. PMID: 16609053 Review.
256 results
Jump to page
Feedback